Top

Published in:

Open Access 01-12-2020 | Multiple Sclerosis | Review

State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis

Authors: María José Sá, Ricardo Soares dos Reis, Ayse Altintas, Elisabeth Gulowsen Celius, Claudia Chien, Giancarlo Comi, Francesc Graus, Jan Hillert, Jeremy Hobart, Gulfaraz Khan, Najib Kissani, Dawn Langdon, Maria Isabel Leite, Darin T. Okuda, Jacqueline Palace, Regina María Papais-Alvarenga, Inês Mendes-Pinto, Fu-Dong Shi

Published in: Neurology and Therapy | Issue 2/2020

Abstract

The 5th International Porto Congress of Multiple Sclerosis took place between the 14th and 16th of February 2019 in Porto, Portugal. Its intensive programme covered a wide-range of themes—including many of the hot topics, challenges, pitfalls and yet unmet needs in the field of multiple sclerosis (MS)—led by a number of well-acknowledged world experts. This meeting review summarizes the talks that took place during the congress, which focussed on issues in MS as diverse as the development and challenges of progressive MS, epidemiology, differential diagnosis, medical management, molecular research and imaging tools.

Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. Lancet. 2018;6736:1–15. https://doi.org/10.1016/S0140-6736(18)30481-1.CrossRef

Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73. https://doi.org/10.1016/S1474-4422(17)30470-2.CrossRefPubMed

Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol. 2014;27:271–8. https://doi.org/10.1097/WCO.0000000000000094.CrossRefPubMedPubMedCentral

Luchetti S, Fransen NL, van Eden CG, et al. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis. Acta Neuropathol. 2018;135:511–28. https://doi.org/10.1007/s00401-018-1818-y.CrossRefPubMedPubMedCentral

Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78:710–21. https://doi.org/10.1002/ana.24497.CrossRefPubMedPubMedCentral

Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012;8:647–56. https://doi.org/10.1038/nrneurol.2012.168.CrossRefPubMed

Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128:2705–12. https://doi.org/10.1093/brain/awh641.CrossRefPubMed

Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72(Suppl 1):1–5. https://doi.org/10.1159/000367614.CrossRefPubMed

Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577–89. https://doi.org/10.1038/s41582-018-0058-z.CrossRefPubMed

10.

Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs. 2011;25:13–25. https://doi.org/10.2165/11539590-000000000-00000.CrossRefPubMed

11.

Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167:1035–47. https://doi.org/10.1111/j.1476-5381.2012.02061.x.CrossRefPubMedPubMedCentral

12.

Multiple Sclerosis International Federation. Atlas of multiple sclerosis 2013—mapping multiple sclerosis around the world. 2013. https://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf. Accessed 15 May 2019.

13.

Börü ÜT, Duman A, Kulualp AS, et al. Multiple sclerosis prevalence study. Medicine (Baltimore). 2018;97:e12856.CrossRef

14.

Akdemir N, Terzi M, Arslan N, et al. Prevalence of multiple sclerosis in the middle black sea region of Turkey and demographic characteristics of patients. Arch Neuropsychiatry. 2017;54:11–4. https://doi.org/10.5152/npa.2016.12451.CrossRef

15.

Börü ÜT, Taşdemir M, Güler N, et al. Prevalence of multiple sclerosis: door-to-door survey in three rural areas of coastal black sea regions of Turkey. Neuroepidemiology. 2011;37:231–5. https://doi.org/10.1159/000334316.CrossRefPubMed

16.

Börü ÜT, Alp R, Sur H, et al. Prevalence of multiple sclerosis door-to-door survey in Maltepe, Istanbul, Turkey. Neuroepidemiology. 2006;27:17–211. https://doi.org/10.1159/000093895.CrossRef

17.

Ait Ben Haddou E, Alhyan M, Aasfara J, et al. Multiple sclerosis: clinical characteristics and disability progression in Moroccan children. J Neurol Sci. 2014;346:128–32. https://doi.org/10.1016/j.jns.2014.08.008.CrossRefPubMed

18.

Araqi-Houssaini A, Lahlou I, Benkadmir Y, et al. Multiple sclerosis severity score in a cohort of Moroccan patients. Mult Scler. 2014;20:764–5. https://doi.org/10.1177/1352458513506504.CrossRefPubMed

19.

Sidhom Y, Maillart E, du Montcel ST, et al. Fast multiple sclerosis progression in North Africans—both genetics and environment matter. Neurology. 2017;88:1218–25.CrossRefPubMed

20.

Bennett J, de Seze J, Lana-Peixoto M, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler J. 2015;21:678–88. https://doi.org/10.1177/1352458514567216.CrossRef

21.

Yang C-S, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology. 2013;81:710–3.CrossRefPubMedPubMedCentral

22.

Zhang C, Tian D, Yang C, et al. Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder. JAMA Neurol. 2017;74:1010–2.CrossRefPubMedPubMedCentral

23.

Cristiano E, Romano M, Frider N, et al. The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review. Mult Scler J. 2013;19:844–54. https://doi.org/10.1177/1352458512462918.CrossRef

24.

Beatriz A, Nogueira C, Clinete M, et al. Prevalence of multiple sclerosis in Brazil: a systematic review. Mult Scler Relat Disord. 2015;4:572–9. https://doi.org/10.1016/j.msard.2015.08.004.CrossRef

25.

Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci. 2001;22:117–39.CrossRefPubMed

26.

Correale J, Gaitán MI. Multiple sclerosis and environmental factors: the role of vitamin D, parasites, and Epstein–Barr virus infection. Acta Neurol Scand. 2015;132:46–55. https://doi.org/10.1111/ane.12431.CrossRefPubMed

27.

Papais-Alvarenga RM, Vasconcelos CCF, Carra A, et al. Central nervous system idiopathic inflammatory demyelinating disorders in South Americans: a descriptive, multicenter, cross-sectional study. PLoS ONE. 2015;10:e0127757. https://doi.org/10.1371/journal.pone.0127757.CrossRefPubMedPubMedCentral

28.

Hillert J, Stawiarz L. The Swedish MS registry—clinical support tool and scientific resource. Acta Neurol Scand. 2015;132:11–9. https://doi.org/10.1111/ane.12425.CrossRefPubMedPubMedCentral

29.

Manouchehrinia A, Beiki O, Hillert J. Clinical course of multiple sclerosis: a nationwide cohort study. Mult Scler. 2017;23:1488–95. https://doi.org/10.1177/1352458516681197.CrossRefPubMed

30.

Gyllensten H, Wiberg M, Alexanderson K, et al. Comparing costs of illness of multiple sclerosis in three different years: a population-based study. Mult Scler J. 2018;24:520–8. https://doi.org/10.1177/https.CrossRef

31.

Westerlind H, Stawiarz L, Fink K, et al. A significant decrease in diagnosis of primary progressive multiple sclerosis: a cohort study. Mult Scler J. 2016;22:1071–9. https://doi.org/10.1177/1352458516643394.CrossRef

32.

Manouchehrinia A, Zhu F, Piani-meier D, et al. Predicting risk of secondary progression in multiple sclerosis: a nomogram. Mult Scler J. 2018. https://doi.org/10.1177/1352458518783667.CrossRef

33.

Gyllensten H, Kavaliunas A, Alexanderson K, et al. Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden. Mult Scler J Exp Transl Clin. 2018. https://doi.org/10.1177/2055217318783352.CrossRefPubMedPubMedCentral

34.

Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler J. 2012;19:765–74. https://doi.org/10.1177/1352458512463764.CrossRef

35.

Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler J. 2017;23:1233–40. https://doi.org/10.1177/1352458516675039.CrossRef

36.

Landfeldt E, Castelo A, Axel B, et al. The long-term impact of early treatment of multiple sclerosis on the risk of disability pension. J Neurol. 2018;265:701–7. https://doi.org/10.1007/s00415-018-8764-4.CrossRefPubMedPubMedCentral

37.

Ramanujam R, Hedström A-K, Manouchehrinia A, et al. Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol. 2015;72:1117–23. https://doi.org/10.1001/jamaneurol.2015.1788.CrossRefPubMed

38.

Brownlee WJ, Hardy TA, Fazekas F, et al. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389:1336–46. https://doi.org/10.1016/S0140-6736(16)30959-X.CrossRefPubMed

39.

Corsellis JA, Goldberg GJ, Norton AR. ‘Limbic encephalitis’ and its association with carcinoma. Brain. 1968;91:481–96.CrossRefPubMed

40.

Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378:840–51. https://doi.org/10.1056/NEJMra1708712.CrossRefPubMed

41.

Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404. https://doi.org/10.1016/S1474-4422(15)00401-9.CrossRefPubMedPubMedCentral

42.

Armangue T, Spatola M, Vlagea A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018;17:760–72. https://doi.org/10.1016/S1474-4422(18)30244-8.CrossRefPubMedPubMedCentral

43.

Ariño H, Armangué T, Petit-Pedrol M, et al. Anti-LGI1–associated cognitive impairment Presentation and long-term outcome. Neurology. 2016;87:759–65.CrossRefPubMedPubMedCentral

44.

Titulaer MJ, McCracken L, Gabilondo II, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65. https://doi.org/10.1016/S1474-4422(12)70310-1.CrossRefPubMedPubMedCentral

45.

Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140:3128–38. https://doi.org/10.1093/brain/awx276.CrossRefPubMed

46.

Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults—the MOGADOR study. Neurology. 2018;90:e1858–e18691869. https://doi.org/10.1212/WNL.0000000000005560.CrossRefPubMed

47.

Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013;80:1330–7.CrossRefPubMedPubMedCentral

48.

Juryńczyk M, Jacob A, Fujihara K, et al. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Pract Neurol. 2018. https://doi.org/10.1136/practneurol-2017-001787.CrossRefPubMed

49.

Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2018;75:478–87. https://doi.org/10.1001/jamaneurol.2017.4601.CrossRefPubMedPubMedCentral

50.

Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg psychiatry. 2018;89:127–37. https://doi.org/10.1136/jnnp-2017-316880.CrossRefPubMed

51.

Giovannoni G, Butzkueven H, Dhib-Jalbut S et al. Brain health—time matters in multiple sclerosis. 2015. https://www.msbrainhealth.org/perch/resources/brain-health-time-matters-in-multiple-sclerosis-sep-17-2.pdf. Accessed 15 May 2019.

52.

Hobart J, Bowen A, Pepper G, et al. International consensus on quality standards for brain health-focused care in multiple sclerosis. Mult Scler. 2018. https://doi.org/10.1177/1352458518809326.CrossRefPubMedPubMedCentral

53.

Langdon DW. Cognition in multiple sclerosis. Curr Opin Neurol. 2011;24:244–9. https://doi.org/10.1097/WCO.0b013e328346a43b.CrossRefPubMed

54.

Sokolov AA, Grivaz P, Bove R. Cognitive deficits in multiple sclerosis: recent advances in treatment and neurorehabilitation. Curr Treat Options Neurol. 2018;20:53. https://doi.org/10.1007/s11940-018-0538-x.CrossRefPubMed

55.

Kobelt G, Langdon D, Jonsson L. The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: the case of multiple sclerosis. Mult Scler. 2019; 25(5):740–9. https://doi.org/10.1177/1352458518769837.CrossRefPubMed

56.

Kavaliunas A, Danylaite Karrenbauer V, Gyllensten H, et al. Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability. Mult Scler. 2019;25:104–12. https://doi.org/10.1177/1352458517740212.CrossRefPubMed

57.

Zipoli V, Goretti B, Hakiki B, et al. Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. Mult Scler. 2010;16:62–7. https://doi.org/10.1177/1352458509350311.CrossRefPubMed

58.

Deloire M, Ruet A, Hamel D, et al. Early cognitive impairment in multiple sclerosis predicts disability outcome several years later. Mult Scler. 2010;16:581–7. https://doi.org/10.1177/1352458510362819.CrossRefPubMed

59.

Moccia M, Lanzillo R, Palladino R, et al. Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. Mult Scler. 2016;22:659–67. https://doi.org/10.1177/1352458515599075.CrossRefPubMed

60.

Bruce JM, Hancock LM, Arnett P, et al. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med. 2010;33:219–27. https://doi.org/10.1007/s10865-010-9247-y.CrossRefPubMed

61.

Muhlert N, Sethi V, Cipolotti L, et al. The grey matter correlates of impaired decision-making in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:530–6. https://doi.org/10.1136/jnnp-2014-308169.CrossRefPubMed

62.

Radomski AD, Power C, Purdon SE, et al. Decision-making under explicit risk is impaired in multiple sclerosis: relationships with ventricular width and disease disability. BMC Neurol. 2015;15:61. https://doi.org/10.1186/s12883-015-0318-0.CrossRefPubMedPubMedCentral

63.

Vahter L, Zopp I, Kreegipuu M, et al. Clean intermittent self-catheterization in persons with multiple sclerosis: the influence of cognitive dysfunction. Mult Scler. 2009;15:379–84. https://doi.org/10.1177/1352458508098599.CrossRefPubMed

64.

Kalron A. The relationship between specific cognitive domains, fear of falling, and falls in people with multiple sclerosis. Biomed Res Int. 2014;2014:281760. https://doi.org/10.1155/2014/281760.CrossRefPubMedPubMedCentral

65.

van Vliet R, Hoang P, Lord S, et al. Multiple sclerosis severity and concern about falling: physical, cognitive and psychological mediating factors. NeuroRehabilitation. 2015;37:139–47. https://doi.org/10.3233/NRE-151246.CrossRefPubMed

66.

Khalil H, Al-Shorman A, El-Salem K, et al. Fear of falling in people with multiple sclerosis: which clinical characteristics are important? Phys Ther. 2017;97:698–706. https://doi.org/10.1093/ptj/pzx044.CrossRefPubMed

67.

D’Orio VL, Foley FW, Armentano F, et al. Cognitive and motor functioning in patients with multiple sclerosis: neuropsychological predictors of walking speed and falls. J Neurol Sci. 2012;316:42–6. https://doi.org/10.1016/j.jns.2012.02.003.CrossRefPubMed

68.

Sosnoff JJ, Balantrapu S, Pilutti LA, et al. Cognitive processing speed is related to fall frequency in older adults with multiple sclerosis. Arch Phys Med Rehabil. 2013;94:1567–72. https://doi.org/10.1016/j.apmr.2013.02.009.CrossRefPubMed

69.

Gunn HJ, Newell P, Haas B, et al. Identification of risk factors for falls in multiple sclerosis: a systematic review and meta-analysis. Phys Ther. 2013;93:504–13. https://doi.org/10.2522/ptj.20120231.CrossRefPubMed

70.

Wajda DA, Moon Y, Motl RW, et al. Preliminary investigation of gait initiation and falls in multiple sclerosis. Arch Phys Med Rehabil. 2015;96:1098–102. https://doi.org/10.1016/j.apmr.2014.12.011.CrossRefPubMed

71.

Etemadi Y. Dual task cost of cognition is related to fall risk in patients with multiple sclerosis: a prospective study. Clin Rehabil. 2017;31:278–84. https://doi.org/10.1177/0269215516637201.CrossRefPubMed

72.

Schultheis MT, Weisser V, Ang J, et al. Examining the relationship between cognition and driving performance in multiple sclerosis. Arch Phys Med Rehabil. 2010;91:465–73. https://doi.org/10.1016/j.apmr.2009.09.026.CrossRefPubMed

73.

Marcotte TD, Rosenthal TJ, Roberts E, et al. The contribution of cognition and spasticity to driving performance in multiple sclerosis. Arch Phys Med Rehabil. 2008;89:1753–8. https://doi.org/10.1016/j.apmr.2007.12.049.CrossRefPubMedPubMedCentral

74.

Badenes D, Garolera M, Casas L, et al. Driving competences and neuropsychological factors associated to driving counseling in multiple sclerosis. J Int Neuropsychol Soc. 2014;20:555–65. https://doi.org/10.1017/S1355617714000368.CrossRefPubMed

75.

Lamargue-Hamel D, Deloire M, Saubusse A, et al. Cognitive evaluation by tasks in a virtual reality environment in multiple sclerosis. J Neurol Sci. 2015;359:94–9. https://doi.org/10.1016/j.jns.2015.10.039.CrossRefPubMed

76.

Benedict RH, Drake AS, Irwin LN, et al. Benchmarks of meaningful impairment on the MSFC and BICAMS. Mult Scler. 2016;22:1874–82. https://doi.org/10.1177/1352458516633517.CrossRefPubMed

77.

Hanna J, Feinstein A, Morrow SA. The association of pathological laughing and crying and cognitive impairment in multiple sclerosis. J Neurol Sci. 2016;361:200–3. https://doi.org/10.1016/j.jns.2016.01.002.CrossRefPubMed

78.

Morrow SA, Rosehart H, Pantazopoulos K, et al. Anxiety and depressive symptoms are associated with worse performance on objective cognitive tests in MS. J Neuropsychiatry Clin Neurosci. 2016;28:118–23. https://doi.org/10.1176/appi.neuropsych.15070167.CrossRefPubMed

79.

Goverover Y, Haas S, DeLuca J. Money management activities in persons with multiple sclerosis. Arch Phys Med Rehabil. 2016;97:1901–7. https://doi.org/10.1016/j.apmr.2016.05.003.CrossRefPubMed

80.

Gerstenecker A, Myers T, Lowry K, et al. Financial capacity and its cognitive predictors in progressive multiple sclerosis. Arch Clin Neuropsychol. 2017;32:943–50. https://doi.org/10.1093/arclin/acx039.CrossRefPubMed

81.

Shevil EBA, Johansson S, Ytterberg C, et al. How are cognitive impairment, fatigue and signs of depression related to participation in daily life among persons with multiple sclerosis? Disabil Rehabil. 2014;36:2012–8. https://doi.org/10.3109/09638288.2014.887797.CrossRef

82.

Vanner EA, Block P, Christodoulou CC, et al. Pilot study exploring quality of life and barriers to leisure-time physical activity in persons with moderate to severe multiple sclerosis. Disabil Health J. 2008;1:58–655. https://doi.org/10.1016/j.dhjo.2007.11.001.CrossRefPubMed

83.

Cattaneo D, Lamers I, Bertoni R, et al. Participation restriction in people with multiple sclerosis: prevalence and correlations with cognitive, walking, balance, and upper limb impairments. Arch Phys Med Rehabil. 2017;98:1308–15. https://doi.org/10.1016/j.apmr.2017.02.015.CrossRefPubMed

84.

Hughes AJ, Hartoonian N, Parmenter B, et al. Cognitive impairment and community integration outcomes in individuals living with multiple sclerosis. Arch Phys Med Rehabil. 2015;96:1973–9. https://doi.org/10.1016/j.apmr.2015.07.003.CrossRefPubMed

85.

Goverover Y, Strober L, Chiaravalloti N, et al. Factors that moderate activity limitation and participation restriction in people with multiple sclerosis. Am J Occup Ther. 2015. https://doi.org/10.5014/ajot.2015.014332.CrossRefPubMed

86.

Chalah MA, Ayache SS. Deficits in social cognition: an unveiled signature of multiple sclerosis. J Int Neuropsychol Soc. 2017;23:266–86. https://doi.org/10.1017/S1355617716001156.CrossRefPubMed

87.

Dulau C, Deloire M, Diaz H, et al. Social cognition according to cognitive impairment in different clinical phenotypes of multiple sclerosis. J Neurol. 2017;264:740–8. https://doi.org/10.1007/s00415-017-8417-z.CrossRefPubMed

88.

Labiano-Fontcuberta A, Mitchell AJ, Moreno-Garcia S, et al. Cognitive impairment in patients with multiple sclerosis predicts worse caregiver’s health-related quality of life. Mult Scler. 2014;20:1769–79. https://doi.org/10.1177/1352458514532398.CrossRefPubMed

89.

Labiano-Fontcuberta A, Mitchell AJ, Moreno-Garcia S, et al. Anxiety and depressive symptoms in caregivers of multiple sclerosis patients: the role of information processing speed impairment. J Neurol Sci. 2015;349:220–5. https://doi.org/10.1016/j.jns.2015.01.024.CrossRefPubMed

90.

Benedict RHB, Munschauer F, Linn R, et al. Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler. 2003;9:95–101. https://doi.org/10.1191/1352458503ms861oa.CrossRefPubMed

91.

Akbar N, Honarmand K, Feinstein A. Self-assessment of cognition in multiple sclerosis: the role of personality and anxiety. Cogn Behav Neurol. 2011;24:115–21. https://doi.org/10.1097/WNN.0b013e31822a20ae.CrossRefPubMed

92.

Beier M, Amtmann D, Ehde DM. Beyond depression: Predictors of self-reported cognitive function in adults living with MS. Rehabil Psychol. 2015;60:254–62. https://doi.org/10.1037/rep0000045.CrossRefPubMedPubMedCentral

93.

Hughes AJ, Beier M, Hartoonian N, et al. Self-efficacy as a longitudinal predictor of perceived cognitive impairment in individuals with multiple sclerosis. Arch Phys Med Rehabil. 2015;96:913–9. https://doi.org/10.1016/j.apmr.2015.01.008.CrossRefPubMedPubMedCentral

94.

Langdon DW, Amato MP, Boringa J, et al. Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). Mult Scler. 2012;18:891–8. https://doi.org/10.1177/1352458511431076.CrossRefPubMedPubMedCentral

95.

Kim S-H, Mealy MA, Levy M, et al. Racial differences in neuromyelitis optica spectrum disorder. Neurology. 2018;91:e2089–e20992099. https://doi.org/10.1212/WNL.0000000000006574.CrossRefPubMedPubMedCentral

96.

Bourre B, Marignier R, Zéphir H, et al. Neuromyelitis optica and pregnancy. Neurology. 2012;78:875–9. https://doi.org/10.1212/WNL.0b013e31824c466f.CrossRefPubMed

97.

Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004;127:1353–60. https://doi.org/10.1093/brain/awh152.CrossRefPubMed

98.

Kim W, Kim S-H, Nakashima I, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology. 2012;78:1264–7. https://doi.org/10.1212/WNL.0b013e318250d812.CrossRefPubMed

99.

Shimizu Y, Fujihara K, Ohashi T, et al. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder. Mult Scler. 2016;22:1413–20. https://doi.org/10.1177/1352458515583376.CrossRefPubMed

100.

Nour MM, Coutinho E, George J, et al. Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology. 2016;86:79–877. https://doi.org/10.1212/WNL.0000000000002208.CrossRefPubMedPubMedCentral

101.

Houtchens MK, Edwards NC, Schneider G, et al. Pregnancy rates and outcomes in women with and without MS in the United States. Neurology. 2018;91:e1559–e15691569. https://doi.org/10.1212/WNL.0000000000006384.CrossRefPubMedPubMedCentral

102.

Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med. 1998;339:285–91. https://doi.org/10.1056/NEJM199807303390501.CrossRefPubMed

103.

Bsteh G, Algrang L, Hegen H, et al. Pregnancy and multiple sclerosis in the DMT era: a cohort study in Western Austria. Mult Scler. 2018. https://doi.org/10.1177/1352458518816614.CrossRefPubMed

104.

Nguyen A-L, Havrdova EK, Horakova D, et al. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study. Mult Scler Relat Disord. 2019;28:235–43. https://doi.org/10.1016/j.msard.2019.01.003.CrossRefPubMed

105.

Celius EG, Ciplea AI, Drulović J, et al. Alemtuzumab and pregnancy—case series from the German MS and Pregnancy Registry, Norway and Serbia. In: Poster Session 2: Poster P915. Mult Scler J. 2018;24:328–529. https://doi.org/10.1177/1352458518798590.

106.

Langer-Gould A, Smith JB, Hellwig K, et al. Breastfeeding, ovulatory years, and risk of multiple sclerosis. Neurology. 2017;89:563–9. https://doi.org/10.1212/WNL.0000000000004207.CrossRefPubMedPubMedCentral

107.

Voskuhl R, Momtazee C. Pregnancy: effect on multiple sclerosis, treatment considerations, and breastfeeding. Neurotherapeutics. 2017;14:974–84. https://doi.org/10.1007/s13311-017-0562-7.CrossRefPubMedPubMedCentral

108.

Khan G, Coates PJ, Gupta RK, et al. Presence of Epstein–Barr virus in Hodgkin’s disease is not exclusive to Reed-Sternberg cells. Am J Pathol. 1992;140:757–62.PubMedPubMedCentral

109.

Khan G, Coates PJ, Kangro HO, et al. Epstein Barr virus (EBV) encoded small RNAs: targets for detection by in situ hybridisation with oligonucleotide probes. J Clin Pathol. 1992;45:616–20.CrossRefPubMedPubMedCentral

110.

Khan G, Norton AJ, Slavin G. Epstein–Barr virus in Hodgkin disease. Relation to age and subtype. Cancer. 1993;71:3124–9.CrossRefPubMed

111.

Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein–Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest. 2005;115:1352–60. https://doi.org/10.1172/JCI23661.CrossRefPubMedPubMedCentral

112.

Haahr S, Plesner AM, Vestergaard BF, et al. A role of late Epstein–Barr virus infection in multiple sclerosis. Acta Neurol Scand. 2004;109:270–5. https://doi.org/10.1046/j.1600-0404.2003.00221.x.CrossRefPubMed

113.

Ponsonby A-L, van der Mei I, Dwyer T, et al. Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA. 2005;293:463–9. https://doi.org/10.1001/jama.293.4.463.CrossRefPubMed

114.

Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein–Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204:2899–912. https://doi.org/10.1084/jem.20071030.CrossRefPubMedPubMedCentral

115.

Opsahl ML, Kennedy PGE. An attempt to investigate the presence of Epstein Barr virus in multiple sclerosis and normal control brain tissue. J Neurol. 2007;254:425–30. https://doi.org/10.1007/s00415-006-0316-7.CrossRefPubMed

116.

Willis SN, Stadelmann C, Rodig SJ, et al. Epstein–Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009;132:3318–28. https://doi.org/10.1093/brain/awp200.CrossRefPubMedPubMedCentral

117.

Sargsyan SA, Shearer AJ, Ritchie AM, et al. Absence of Epstein–Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology. 2010;74:1127–35. https://doi.org/10.1212/WNL.0b013e3181d865a1.CrossRefPubMedPubMedCentral

118.

Aloisi F, Serafini B, Magliozzi R, et al. Detection of Epstein–Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. Brain. 2010;133:e157. https://doi.org/10.1093/brain/awq223.CrossRefPubMed

119.

Hassani A, Corboy JR, Al-Salam S, et al. Epstein–Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS ONE. 2018;13:e0192109. https://doi.org/10.1371/journal.pone.0192109.CrossRefPubMedPubMedCentral

120.

Tzartos JS, Khan G, Vossenkamper A, et al. Association of innate immune activation with latent Epstein–Barr virus in active MS lesions. Neurology. 2012;78:15–23. https://doi.org/10.1212/WNL.0b013e31823ed057.CrossRefPubMed

121.

Khan G, Ahmed W, Philip PS, et al. Healthy rabbits are susceptible to Epstein–Barr virus infection and infected cells proliferate in immunosuppressed animals. Virol J. 2015;12:28. https://doi.org/10.1186/s12985-015-0260-1.CrossRefPubMedPubMedCentral

122.

Abreu CM, Soares-Dos-Reis R, Melo PN, et al. Emerging biosensing technologies for neuroinflammatory and neurodegenerative disease diagnostics. Front Mol Neurosci. 2018;11:164. https://doi.org/10.3389/fnmol.2018.00164.CrossRefPubMedPubMedCentral

123.

Cruz A, Queiros R, Abreu CM, et al. Electrochemical immunosensor for TNFalpha-mediated inflammatory disease screening. ACS Chem Neurosci. 2019;10:2676–82. https://doi.org/10.1021/acschemneuro.9b00036.CrossRefPubMed

124.

Maggi P, Absinta M, Grammatico M, et al. Central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol. 2018;83:283–94. https://doi.org/10.1002/ana.25146.CrossRefPubMedPubMedCentral

125.

Glasser MF, Van Essen DC, Manuscript A, et al. Mapping human cortical areas in vivo based on myelin content as revealed by T1- and T2-weighted MRI. J Neurosci. 2011;31:11597–616. https://doi.org/10.1523/JNEUROSCI.2180-11.2011.CrossRefPubMedPubMedCentral

126.

Glasser MF, Coalson TS, Robinson EC, et al. A multi-modal parcellation of human cerebral cortex. Nature. 2016;536:171–8. https://doi.org/10.1038/nature18933.CrossRefPubMedPubMedCentral

127.

Backner Y, Kuchling J, Massarwa S, et al. Anatomical wiring and functional networking changes in the visual system following optic neuritis. JAMA Neurol. 2018;75:287–95. https://doi.org/10.1001/jamaneurol.2017.3880.CrossRefPubMedPubMedCentral

128.

Finke C, Zimmermann H, Pache F, et al. Association of visual impairment in neuromyelitis optica spectrum disorder with visual network reorganization visual network reorganization in neuromyelitis optica spectrum disorder visual network reorganization in neuromyelitis optica spectrum disorder. JAMA Neurol. 2018;75:296–303. https://doi.org/10.1001/jamaneurol.2017.3890.CrossRefPubMedPubMedCentral

129.

Ciccarelli O, Cohen JA, Reingold SC, et al. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurol. 2019;18:185–97. https://doi.org/10.1016/S1474-4422(18)30460-5.CrossRefPubMed

130.

Gros C, De Leener B, Badji A, et al. Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. Neuroimage. 2019;184:901–15. https://doi.org/10.1016/j.neuroimage.2018.09.081.CrossRefPubMed

131.

Petzold A, Balcer LJ, Calabresi PA, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2017;16:797–812. https://doi.org/10.1016/S1474-4422(17)30278-8.CrossRefPubMed

132.

Zimmermann HG, Knier B, Oberwahrenbrock T, et al. Association of retinal ganglion cell layer thickness with future disease activity in patients with clinically isolated syndrome. JAMA Neurol. 2018;75:1071–9. https://doi.org/10.1001/jamaneurol.2018.1011.CrossRefPubMedPubMedCentral

133.

Oertel FC, Havla J, Roca-Fernandez A, et al. Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. J Neurol Neurosurg Psychiatry. 2018;89:1259–65. https://doi.org/10.1136/jnnp-2018-318382.CrossRefPubMed

134.

Xu SC, Kardon RH, Leavitt JA, et al. Optical coherence tomography is highly sensitive in detecting prior optic neuritis. Neurology. 2019;92:e527–e535535. https://doi.org/10.1212/WNL.0000000000006873.CrossRefPubMed

135.

Kantarci OH, Lebrun C, Siva A, et al. Primary progressive multiple sclerosis evolving from radiologically isolated syndrome. Ann Neurol. 2016;79:288–94. https://doi.org/10.1002/ana.24564.CrossRefPubMed

Title: State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis
Authors: María José Sá
Ricardo Soares dos Reis
Ayse Altintas
Elisabeth Gulowsen Celius
Claudia Chien
Giancarlo Comi
Francesc Graus
Jan Hillert
Jeremy Hobart
Gulfaraz Khan
Najib Kissani
Dawn Langdon
Maria Isabel Leite
Darin T. Okuda
Jacqueline Palace
Regina María Papais-Alvarenga
Inês Mendes-Pinto
Fu-Dong Shi
Publication date: 01-12-2020
Publisher: Springer Healthcare
Keywords: Multiple Sclerosis
Demyelinating Disease
Published in: Neurology and Therapy / Issue 2/2020
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI: https://doi.org/10.1007/s40120-020-00202-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Treatment Options for Dementia with Lewy Bodies: A Network Meta-Analysis of Randomised Control Trials

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis

The Humanistic and Economic Burden of Migraine in Europe: A Cross-Sectional Survey in Five Countries

Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy

A Review of the Recent Findings in Minimally Invasive Treatment Options for the Management of Occipital Neuralgia

CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer’s Disease—A Narrative Review